Updates are available Correction dated 2024-07-18

Article History

Received: 5 November 2020

Accepted: 20 January 2021

First Online: 18 March 2021

Change Date: 18 July 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00774-024-01522-6

Compliance with ethical standards

:

: HH has received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd., and UCB Japan. YU has received a consultancy fee from Teijin Pharma Ltd. and Daiichi Sankyo and outsourcing fees from Chugai Pharmaceutical Co. SM and HO have nothing to disclose. TS has received research grants from Asahi Kasei Pharma Corp., Astellas Pharma, Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer, and Teijin Pharma Ltd., and consulting fees from Kissei pharmaceutical Co. Ltd., Shimadzu Corp., and Takeda Pharmaceutical Co. Ltd. TN has received personal fees and other from Asahi Pharma, Teijin Pharma, Daiichi-Sankyo Pharma, UCB Pharma, AMGEN, ASTELAS, Chugai Pharma, and MERCK.

: This study was registered at the University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) under trial identification number UMIN000005433. The protocol was approved by the Central Ethical committee for Adequate Treatment of Osteoporosis (A-TOP) group (Dr. Rikushi Morita, Chairman) and was reviewed by the institutional review board of each participating institution. The trial was conducted in accordance with the Declaration of Helsinki.

: Written, informed consent was obtained prior to patient enrollment after a thorough explanation of the trial objectives, duration, and procedures.